Gene therapy to treat haemophilia

0

The exclusive, global collaboration and license agreement for the development and commercialization of gene therapy programs for Haemophilia A has been signed between Sangamo Therapeutics and Pfizer. It will include SB-525, one of Sangamo’s four lead product candidates, which has been granted orphan drug designation by the FDA and is expected to soon enter human clinical trials. Sangamo will receive a $70 million upfront payment from Pfizer and it will be responsible for conducting the SB-525 Phase 1/2 clinical study and certain manufacturing activities. Pfizer will be operationally and financially responsible for subsequent research, development, manufacturing and commercialization activities for SB-525 and additional products, if any.

 

SHARE

LEAVE A REPLY

Please enter your comment!
Please enter your name here